Protara Therapeutics, Inc.
TARA
$3.97
-$0.07-1.73%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -2.74% | -30.54% | 11.38% | -25.57% | 6.70% |
| Total Depreciation and Amortization | -3.23% | 5.68% | -10.20% | 18.07% | 1.22% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 46.23% | 7.68% | 14.93% | -13.55% | 5.20% |
| Change in Net Operating Assets | -598.50% | -254.85% | -111.39% | 147.43% | -252.79% |
| Cash from Operations | -25.92% | -36.12% | -1.65% | 16.74% | -58.07% |
| Capital Expenditure | -- | -500.00% | 81.82% | 50.00% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 45.24% | -313.47% | 86.37% | 18.19% | -359.16% |
| Cash from Investing | 45.29% | -313.59% | 86.37% | 18.22% | -359.35% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -97.61% | -- | -- | -91.91% | -97.36% |
| Repurchase of Common Stock | -- | 100.00% | -- | 100.00% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -145.79% | -200.00% | 200.00% | 74.15% | 86.32% |
| Cash from Financing | -98.59% | 622,700.00% | 62.50% | -99.54% | -98.23% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -194.11% | 295.86% | 68.41% | 15.94% | -164.24% |